ATE431359T1 - Copolymer-1-verwandte polypeptide für die verwendung als molekulargewichtsmarker und zur therapie - Google Patents

Copolymer-1-verwandte polypeptide für die verwendung als molekulargewichtsmarker und zur therapie

Info

Publication number: ATE431359T1
Authority: AT; Austria
Prior art keywords: molecular weight; weight markers; therapy; copolymers; copolymer
Prior art date: 1998-09-25

Application number

AT99949923T

Other languages

English (en)

Inventor

Alexander Gad

Dora Lis

Original Assignee

Yeda Res & Dev

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-09-25

Filing date

1999-09-24

Publication date

2009-05-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22285926&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE431359(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1999-09-24 Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev

2009-05-15 Application granted granted Critical

2009-05-15 Publication of ATE431359T1 publication Critical patent/ATE431359T1/de

Links

229920001184 polypeptide Polymers 0.000 title 1
102000004196 processed proteins & peptides Human genes 0.000 title 1
108090000765 processed proteins & peptides Proteins 0.000 title 1
238000002560 therapeutic procedure Methods 0.000 title 1
108010072051 Glatiramer Acetate Proteins 0.000 abstract 3
FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 abstract 3
229920001577 copolymer Polymers 0.000 abstract 3
229960003776 glatiramer acetate Drugs 0.000 abstract 3
230000004071 biological effect Effects 0.000 abstract 1
208000026278 immune system disease Diseases 0.000 abstract 1
230000014759 maintenance of location Effects 0.000 abstract 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Immunology (AREA)
Diabetes (AREA)
Hematology (AREA)
Endocrinology (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Dermatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Biochemistry (AREA)
Rheumatology (AREA)
Neurology (AREA)
Urology & Nephrology (AREA)
Food Science & Technology (AREA)
Analytical Chemistry (AREA)
Emergency Medicine (AREA)
Reproductive Health (AREA)
Pulmonology (AREA)
Epidemiology (AREA)
Biotechnology (AREA)
Cell Biology (AREA)
Microbiology (AREA)
Transplantation (AREA)
Neurosurgery (AREA)

AT99949923T 1998-09-25 1999-09-24 Copolymer-1-verwandte polypeptide für die verwendung als molekulargewichtsmarker und zur therapie ATE431359T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US10169398P	1998-09-25	1998-09-25
PCT/US1999/022402 WO2000018794A1 (en)	1998-09-25	1999-09-24	Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use

Publications (1)

Publication Number	Publication Date
ATE431359T1 true ATE431359T1 (de)	2009-05-15

Family

ID=22285926

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT99949923T ATE431359T1 (de)	1998-09-25	1999-09-24	Copolymer-1-verwandte polypeptide für die verwendung als molekulargewichtsmarker und zur therapie
AT09004306T ATE516297T1 (de)	1998-09-25	1999-09-24	Mit copolymer 1 verwandte polypeptide zur verwendung als molekulargewichtsmarker und zur therapeutischen verwendung

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
AT09004306T ATE516297T1 (de)	1998-09-25	1999-09-24	Mit copolymer 1 verwandte polypeptide zur verwendung als molekulargewichtsmarker und zur therapeutischen verwendung

Country Status (17)

Country	Link
EP (3)	EP2090583B1 (de)
JP (2)	JP4629229B2 (de)
AT (2)	ATE431359T1 (de)
AU (1)	AU757413B2 (de)
CA (2)	CA2794705C (de)
CY (3)	CY1110490T1 (de)
DE (2)	DE09004306T1 (de)
DK (3)	DK2090583T3 (de)
ES (3)	ES2327301T3 (de)
HU (3)	HU229719B1 (de)
IL (4)	IL142116A0 (de)
NO (2)	NO329877B1 (de)
NZ (1)	NZ511020A (de)
PT (3)	PT1115743E (de)
SI (1)	SI1115743T1 (de)
WO (1)	WO2000018794A1 (de)
ZA (1)	ZA200102269B (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2000005250A1 (en)	1998-07-23	2000-02-03	Yeda Research And Development Co., Ltd	Treatment of autoimmune conditions with copolymer 1 and related copolymers and peptides
ES2527760T3 (es)	1998-07-23	2015-01-29	Yeda Research And Development Co., Ltd.	Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
US6800287B2 (en)	1998-09-25	2004-10-05	Yeda Research And Development Co., Ltd.	Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
US7022663B2 (en)	2000-02-18	2006-04-04	Yeda Research And Development Co., Ltd.	Oral, nasal and pulmonary dosage formulations of copolymer 1
US20020077278A1 (en)	2000-06-05	2002-06-20	Yong V. Wee	Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
IL148202A0 (en) *	2000-06-20	2002-09-12	Caprion Pharmaceuticals Inc	Copolymers and methods of treating prion-related diseases
WO2002076503A1 (en)	2000-06-20	2002-10-03	Mayo Foundation For Medical Education And Research	Treatment of central nervous system diseases by antibodies against glatiramer acetate
US20040037828A1 (en) *	2002-07-09	2004-02-26	Bar-Ilan University	Methods and pharmaceutical compositions for healing wounds
IL161121A0 (en)	2001-10-03	2004-08-31	Harvard College	Copolymers for suppression of autoimmune diseases, and methods of use
SI1459065T1 (sl)	2001-12-04	2010-11-30	Teva Pharma	Postopki za merjenje potentnosti glatiramer acetata
NZ569331A (en)	2003-01-21	2010-08-27	Yeda Res & Dev	COP 1 for treatment of inflammatory bowel diseases
WO2005013885A2 (en)	2003-08-07	2005-02-17	Healor Ltd.	Pharmaceutical compositions and methods for accelerating wound healing
KR20060125916A (ko) *	2004-03-01	2006-12-06	펩팀문, 인코포레이티드	자가면역 질병을 치료하기 위한 방법 및 조성물
US7655221B2 (en)	2004-05-07	2010-02-02	Peptimmune, Inc.	Methods of treating disease with random copolymers
WO2006029411A2 (en)	2004-09-09	2006-03-16	Yeda Research And Development Co. Ltd.	Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof
US7858337B2 (en)	2007-03-08	2010-12-28	Novartis Ag	Process for the manufacture of a composite material
ES2612001T4 (es)	2009-08-20	2018-02-07	Yeda Research & Development Company, Ltd.	Terapia de baja frecuencia con acetato de glatirámero
USRE49251E1 (en)	2010-01-04	2022-10-18	Mapi Pharma Ltd.	Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en)	2010-03-16	2014-06-24	Teva Pharmaceutical Industries, Ltd.	Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
NZ703122A (en)	2010-10-11	2016-06-24	Teva Pharma	Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate
CA2827275A1 (en)	2011-02-14	2012-09-20	Usv Limited	Copolymer-1, process for preparation and analytical methods thereof
KR20140101730A (ko)	2011-10-10	2014-08-20	테바 파마슈티컬 인더스트리즈 리미티드	글라티라머 아세테이트에 대한 임상 반응을 예측하는 데 유용한 단일 뉴클레오티드 다형성
MX2015004563A (es)	2012-10-10	2015-07-14	Teva Pharma	Biomarcadores predictivos para respuesta clinica para acetato de glatiramero.
CN104098655B (zh) *	2013-04-09	2018-01-30	深圳翰宇药业股份有限公司	用于合成醋酸格拉替雷的质谱内标的多肽
UY35790A (es)	2013-10-21	2015-05-29	Teva Pharma	Marcadores genéticos que predicen la respuesta al acetato de glatiramer
CN105218646B (zh) *	2014-06-24	2018-09-21	深圳翰宇药业股份有限公司	一种用于检测醋酸格拉替雷样本的uplc方法
US9155775B1 (en)	2015-01-28	2015-10-13	Teva Pharmaceutical Industries, Ltd.	Process for manufacturing glatiramer acetate product
CN112649537B (zh) *	2015-04-28	2024-03-29	深圳翰宇药业股份有限公司	多肽混合物高效液相色谱分析方法
EP3147667B1 (de) *	2015-09-24	2019-06-12	CHEMI S.p.A.	Analyse der molekulargewichtsverteilung von komplexen polypeptidmischungen
US12097292B2 (en)	2016-08-28	2024-09-24	Mapi Pharma Ltd.	Process for preparing microparticles containing glatiramer acetate
HUE071047T2 (hu)	2016-08-31	2025-07-28	Mapi Pharma Ltd	Glatiramer-acetátot tartalmazó depórendszerek
CN110382052A (zh)	2017-03-26	2019-10-25	Mapi医药公司	用于治疗进展型形式的多发性硬化症的格拉替雷储库系统

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2009996A1 (en) *	1989-02-17	1990-08-17	Kathleen S. Cook	Process for making genes encoding random polymers of amino acids
IL113812A (en)	1994-05-24	2000-06-29	Yeda Res & Dev	Copolymer-1 pharmaceutical compositions containing it and its use

1999
- 1999-09-24 SI SI9931035T patent/SI1115743T1/sl unknown
- 1999-09-24 AT AT99949923T patent/ATE431359T1/de active
- 1999-09-24 HU HU1300505A patent/HU229719B1/hu unknown
- 1999-09-24 EP EP09004306A patent/EP2090583B1/de not_active Expired - Lifetime
- 1999-09-24 DE DE09004306T patent/DE09004306T1/de active Pending
- 1999-09-24 DE DE69940888T patent/DE69940888D1/de not_active Expired - Lifetime
- 1999-09-24 AU AU62695/99A patent/AU757413B2/en not_active Expired
- 1999-09-24 ZA ZA200102269A patent/ZA200102269B/en unknown
- 1999-09-24 EP EP10171553A patent/EP2239269B1/de not_active Expired - Lifetime
- 1999-09-24 ES ES99949923T patent/ES2327301T3/es not_active Expired - Lifetime
- 1999-09-24 DK DK09004306.8T patent/DK2090583T3/da active
- 1999-09-24 ES ES09004306T patent/ES2369642T3/es not_active Expired - Lifetime
- 1999-09-24 AT AT09004306T patent/ATE516297T1/de active
- 1999-09-24 PT PT99949923T patent/PT1115743E/pt unknown
- 1999-09-24 DK DK10171553.0T patent/DK2239269T3/da active
- 1999-09-24 WO PCT/US1999/022402 patent/WO2000018794A1/en not_active Ceased
- 1999-09-24 EP EP99949923A patent/EP1115743B1/de not_active Expired - Lifetime
- 1999-09-24 HU HU1300337A patent/HU229720B1/hu unknown
- 1999-09-24 ES ES10171553T patent/ES2408706T3/es not_active Expired - Lifetime
- 1999-09-24 PT PT09004306T patent/PT2090583E/pt unknown
- 1999-09-24 PT PT101715530T patent/PT2239269E/pt unknown
- 1999-09-24 DK DK99949923T patent/DK1115743T3/da active
- 1999-09-24 NZ NZ511020A patent/NZ511020A/xx not_active IP Right Cessation
- 1999-09-24 CA CA2794705A patent/CA2794705C/en not_active Expired - Lifetime
- 1999-09-24 CA CA2343929A patent/CA2343929C/en not_active Expired - Lifetime
- 1999-09-24 IL IL14211699A patent/IL142116A0/xx unknown
- 1999-09-24 JP JP2000572252A patent/JP4629229B2/ja not_active Expired - Lifetime
- 1999-09-24 HU HU0103889A patent/HU229289B1/hu unknown
2001
- 2001-03-20 IL IL142116A patent/IL142116A/en not_active IP Right Cessation
- 2001-03-21 NO NO20011441A patent/NO329877B1/no not_active IP Right Cessation
2009
- 2009-08-06 CY CY20091100835T patent/CY1110490T1/el unknown
2010
- 2010-03-25 NO NO20100442A patent/NO336685B1/no not_active IP Right Cessation
- 2010-06-23 JP JP2010142689A patent/JP4903886B2/ja not_active Expired - Lifetime
- 2010-11-07 IL IL209189A patent/IL209189A/en not_active IP Right Cessation
- 2010-11-07 IL IL209190A patent/IL209190A/en not_active IP Right Cessation
2011
- 2011-10-05 CY CY20111100947T patent/CY1112197T1/el unknown
2013
- 2013-04-15 CY CY20131100310T patent/CY1113932T1/el unknown

Also Published As

Publication number	Publication date
IL209190A0 (en)	2011-01-31
PT1115743E (pt)	2009-07-07
CY1112197T1 (el)	2015-12-09
EP1115743A4 (de)	2005-04-27
ES2369642T3 (es)	2011-12-02
HUP0103889A2 (hu)	2002-03-28
HK1133021A1 (en)	2010-03-12
NO336685B1 (no)	2015-10-19
HK1149279A1 (en)	2011-09-30
CA2794705C (en)	2017-07-18
PT2239269E (pt)	2013-04-09
CY1110490T1 (el)	2015-04-29
NO20011441D0 (no)	2001-03-21
ATE516297T1 (de)	2011-07-15
JP4629229B2 (ja)	2011-02-09
IL209189A (en)	2017-11-30
EP2090583B1 (de)	2011-07-13
ES2408706T3 (es)	2013-06-21
IL142116A0 (en)	2002-03-10
HK1040521A1 (en)	2002-06-14
DK1115743T3 (da)	2009-07-27
NZ511020A (en)	2003-06-30
EP2239269B1 (de)	2013-01-16
PT2090583E (pt)	2011-09-14
HU229719B1 (en)	2014-05-28
DE09004306T1 (de)	2010-12-09
NO329877B1 (no)	2011-01-17
EP1115743A1 (de)	2001-07-18
WO2000018794A1 (en)	2000-04-06
DK2239269T3 (da)	2013-04-29
JP4903886B2 (ja)	2012-03-28
ES2327301T3 (es)	2009-10-27
EP2090583A1 (de)	2009-08-19
DE69940888D1 (de)	2009-06-25
SI1115743T1 (sl)	2010-01-29
NO20011441L (no)	2001-05-25
HU229720B1 (en)	2014-05-28
EP2239269A1 (de)	2010-10-13
HU229289B1 (en)	2013-10-28
CA2343929C (en)	2013-01-29
AU757413B2 (en)	2003-02-20
HUP0103889A3 (en)	2004-03-01
AU6269599A (en)	2000-04-17
CA2343929A1 (en)	2000-04-06
CA2794705A1 (en)	2000-04-06
CY1113932T1 (el)	2016-07-27
IL142116A (en)	2010-12-30
EP1115743B1 (de)	2009-05-13
JP2002525378A (ja)	2002-08-13
DK2090583T3 (da)	2011-09-12
IL209189A0 (en)	2011-01-31
NO20100442L (no)	2001-05-25
IL209190A (en)	2017-11-30
JP2010271325A (ja)	2010-12-02
ZA200102269B (en)	2002-03-19

Legal Events

Date

Code

Title

Description

2009-12-15

UEP

Publication of translation of european patent specification

Ref document number: 1115743

Country of ref document: EP

Publication	Publication Date	Title
ATE431359T1 (de)	2009-05-15	Copolymer-1-verwandte polypeptide für die verwendung als molekulargewichtsmarker und zur therapie
ATE529444T1 (de)	2011-11-15	Inhibitoren des humanplasmins, die sich von den kunitz domänen ableiten
TR200001709T2 (tr)	2001-03-21	Yeni neisseria meningitids yüzey proteini
DE68929430D1 (de)	2002-11-28	Fibronektin bindendes Protein
EE05497B1 (et)	2011-12-15	Polüpeptiid, lahustuv CRAM-1 polüpeptiid, polünukleotiid ja antikeha
FI893681A0 (fi)	1989-08-03	N-2,3-butadienyltri- och tetra-aminoalkanderivat.
DE3673217D1 (de)	1990-09-13	Phenylalkyl-2,3-dihydrobenzofurane und analoga zur verwendung als antientzuendungsmittel.
DE69433902D1 (de)	2004-08-19	Neuartige tyrosinkinase
ATE312179T1 (de)	2005-12-15	Serin-threonin-kinase enthaltendes mittel zur tumortherapie und tumordiagnose
DK0870036T3 (da)	2008-11-24	Syntetisk pattedyrs-alfa-N-acetylglucosaminidase og genetiske sekvenser kodende derfor
ATE242883T1 (de)	2003-06-15	Verfahren zur bestimmung von blutgerinnungsfaktoren viii und ix
DE68902792D1 (de)	1992-10-15	Mittel zur kosmetischen oder pharmazeutischen verwendung.
ATE198218T1 (de)	2001-01-15	Htfiiia gen
ATE530651T1 (de)	2011-11-15	Leishmania antigene für verwendung in der therapie und diagnose von leishmaniose